183 related articles for article (PubMed ID: 38341429)
1. PRL-mediated STAT5B/ARRB2 pathway promotes the progression of prostate cancer through the activation of MAPK signaling.
Yang T; Chi Y; Wang X; Xu C; Chen X; Liu Y; Huang S; Zhu X; Zhang H; Zhuo H; Wu D
Cell Death Dis; 2024 Feb; 15(2):128. PubMed ID: 38341429
[TBL] [Abstract][Full Text] [Related]
2. Prolactin- and testosterone-induced carboxypeptidase-D correlates with increased nitrotyrosines and Ki67 in prostate cancer.
Thomas LN; Merrimen J; Bell DG; Rendon R; Too CK
Prostate; 2015 Nov; 75(15):1726-36. PubMed ID: 26202060
[TBL] [Abstract][Full Text] [Related]
3. Prolactin induces up-regulation of its cognate receptor in breast cancer cells via transcriptional activation of its generic promoter by cross-talk between ERα and STAT5.
Kavarthapu R; Tsai Morris CH; Dufau ML
Oncotarget; 2014 Oct; 5(19):9079-91. PubMed ID: 25193864
[TBL] [Abstract][Full Text] [Related]
4. Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathway.
Dagvadorj A; Collins S; Jomain JB; Abdulghani J; Karras J; Zellweger T; Li H; Nurmi M; Alanen K; Mirtti T; Visakorpi T; Bubendorf L; Goffin V; Nevalainen MT
Endocrinology; 2007 Jul; 148(7):3089-101. PubMed ID: 17412813
[TBL] [Abstract][Full Text] [Related]
5. Carboxypeptidase-D is elevated in prostate cancer and its anti-apoptotic activity is abolished by combined androgen and prolactin receptor targeting.
Thomas LN; Merrimen J; Bell DG; Rendon R; Goffin V; Too CK
Prostate; 2014 May; 74(7):732-42. PubMed ID: 24615730
[TBL] [Abstract][Full Text] [Related]
6. An immunohistochemical approach to monitor the prolactin-induced activation of the JAK2/STAT5 pathway in pancreatic islets of Langerhans.
Brelje TC; Svensson AM; Stout LE; Bhagroo NV; Sorenson RL
J Histochem Cytochem; 2002 Mar; 50(3):365-83. PubMed ID: 11850439
[TBL] [Abstract][Full Text] [Related]
7. The prolactin receptor mediates HOXA1-stimulated oncogenicity in mammary carcinoma cells.
Hou L; Xu B; Mohankumar KM; Goffin V; Perry JK; Lobie PE; Liu DX
Int J Oncol; 2012 Dec; 41(6):2285-95. PubMed ID: 23064471
[TBL] [Abstract][Full Text] [Related]
8. PRL-induced ERalpha gene expression is mediated by Janus kinase 2 (Jak2) while signal transducer and activator of transcription 5b (Stat5b) phosphorylation involves Jak2 and a second tyrosine kinase.
Frasor J; Barkai U; Zhong L; Fazleabas AT; Gibori G
Mol Endocrinol; 2001 Nov; 15(11):1941-52. PubMed ID: 11682625
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional inhibition by Stat5. Differential activities at growth-related versus differentiation-specific promoters.
Luo G; Yu-Lee L
J Biol Chem; 1997 Oct; 272(43):26841-9. PubMed ID: 9341115
[TBL] [Abstract][Full Text] [Related]
10. Changes in prolactin receptor location in prostate tumors.
López Fontana G; Rey L; Santiano F; López Fontana R; López Laur JD; Zyla L; Valdemoros P; Guerrero-Giménez ME; Fernández-Muñoz JM; Gómez S; Bruna F; Guglielmi JM; Carón R; López Fontana C
Arch Esp Urol; 2021 May; 74(4):419-426. PubMed ID: 33942735
[TBL] [Abstract][Full Text] [Related]
11. Growth hormone signaling in human T47D breast cancer cells: potential role for a growth hormone receptor-prolactin receptor complex.
Xu J; Zhang Y; Berry PA; Jiang J; Lobie PE; Langenheim JF; Chen WY; Frank SJ
Mol Endocrinol; 2011 Apr; 25(4):597-610. PubMed ID: 21310852
[TBL] [Abstract][Full Text] [Related]
12. The role of prolactin receptor in GH signaling in breast cancer cells.
Xu J; Sun D; Jiang J; Deng L; Zhang Y; Yu H; Bahl D; Langenheim JF; Chen WY; Fuchs SY; Frank SJ
Mol Endocrinol; 2013 Feb; 27(2):266-79. PubMed ID: 23192981
[TBL] [Abstract][Full Text] [Related]
13. Local prolactin is a target to prevent expansion of basal/stem cells in prostate tumors.
Rouet V; Bogorad RL; Kayser C; Kessal K; Genestie C; Bardier A; Grattan DR; Kelder B; Kopchick JJ; Kelly PA; Goffin V
Proc Natl Acad Sci U S A; 2010 Aug; 107(34):15199-204. PubMed ID: 20699217
[TBL] [Abstract][Full Text] [Related]
14. Essential role of endogenous prolactin and CDK7 in estrogen-induced upregulation of the prolactin receptor in breast cancer cells.
Kavarthapu R; Dufau ML
Oncotarget; 2017 Apr; 8(16):27353-27363. PubMed ID: 28423697
[TBL] [Abstract][Full Text] [Related]
15. STAT5 and prolactin participate in a positive autocrine feedback loop that promotes angiogenesis.
Yang X; Meyer K; Friedl A
J Biol Chem; 2013 Jul; 288(29):21184-21196. PubMed ID: 23729680
[TBL] [Abstract][Full Text] [Related]
16. PRL/PRLR Can Promote Insulin Resistance by Activating the JAK2/STAT5 Signaling Pathway.
Wang PY; Jin CC; Liu C; Zhao ZJ; Yang HY
Comput Math Methods Med; 2022; 2022():1456187. PubMed ID: 36238467
[TBL] [Abstract][Full Text] [Related]
17. Prolactin receptor signaling: A novel target for cancer treatment - Exploring anti-PRLR signaling strategies.
Standing D; Dandawate P; Anant S
Front Endocrinol (Lausanne); 2022; 13():1112987. PubMed ID: 36714582
[TBL] [Abstract][Full Text] [Related]
18. Seasonal expressions of prolactin, prolactin receptor and STAT5 in the scented glands of the male muskrats (Ondatra zibethicus).
Xie W; Liu H; Liu Q; Gao Q; Gao F; Han Y; Yuan Z; Zhang H; Weng Q
Eur J Histochem; 2019 Jan; 63(1):. PubMed ID: 30652434
[TBL] [Abstract][Full Text] [Related]
19. Phospholipase D inhibitors reduce human prostate cancer cell proliferation and colony formation.
Noble AR; Maitland NJ; Berney DM; Rumsby MG
Br J Cancer; 2018 Jan; 118(2):189-199. PubMed ID: 29136407
[TBL] [Abstract][Full Text] [Related]
20. Prolactin receptor targeting in breast and prostate cancers: New insights into an old challenge.
Goffin V
Pharmacol Ther; 2017 Nov; 179():111-126. PubMed ID: 28549597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
